[1]赵鑫龙,杨杰孚.华法林药物基因组学的应用[J].医学信息,2021,34(20):50-53.[doi:10.3969/j.issn.1006-1959.2021.20.012]
　ZHAO Xin-long,YANG Jie-fu.Application of Warfarin Pharmacogenomics[J].Medical Information,2021,34(20):50-53.[doi:10.3969/j.issn.1006-1959.2021.20.012]
点击复制

华法林药物基因组学的应用()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年20期
页码:
50-53
栏目:
综述
出版日期:
2021-10-20

文章信息/Info

Title:
Application of Warfarin Pharmacogenomics
文章编号:
1006-1959（2021）20-0050-04
作者:
赵鑫龙1; 2; 杨杰孚1; 2
1.北京医院心血管内科/国家老年医学中心/中国医学科学院老年医学研究院，北京 100730；2.北京协和医学院研究生院，北京 100005
Author(s):
ZHAO Xin-long1; 2; YANG Jie-fu1; 2
1.Department of Cardiology，Beijing Hospital，National Center of Gerontology/Institute of Geriatric Medicine，Chinese Academy of Medical Sciences，Beijing 100730, P.R. China；2.Graduate School of Peking Union Medical College,Beijing 100005,China
关键词:
华法林; 药物基因组学; 基因多态性; 抗凝
Keywords:
Warfarin; Pharmacogenomics; Genetic polymorphism; Anticoagulation
分类号:
R972+.2；R969.3
DOI:
10.3969/j.issn.1006-1959.2021.20.012
文献标志码:
A
摘要:
华法林具有适应证广、经济且易于拮抗等优点，现已成为临床最常用的口服抗凝药物。但由于不同个体间药物剂量差异，导致其稳态剂量较难预测，造成过度抗凝、出血等不良事件的发生。随着近些年华法林代谢酶的基因组学研究，极大地推动了临床华法林精准治疗、个体化给药等的发展。本文就目前华法林基因组学及其临床应用进展进行阐述，以期为日后基因指导华法林的使用提供理论基础。
Abstract:
Warfarin has been the most commonly used oral anticoagulant drug in clinic because of its wide range of indications, economy and easy antagonism. However, due to the difference of drug dose among different individuals, the steady-state dose is difficult to predict, resulting in excessive anticoagulation, bleeding and other adverse events. In recent years, the genomics research of warfarin metabolic enzymes has greatly promoted the development of clinical warfarin precision therapy and individualized drug administration. In this paper, the genomics and clinical application of warfarin are reviewed, in order to provide a theoretical basis for the use of gene guidance warfarin in the future.

参考文献/References:

[1]Li X,Li D,Wu JC.Precision dosing of warfarin: open questions and strategies[J].Pharmacogenomics J,2019,19(3):219-229.[2]Tavares LC,Marcatto LR,Santos PCJL.Genotype-guided warfarin therapy: current status[J].Pharmacogenomics,2018,19(7):667-685.[3]Flora DR,Rettie AE,Brundage RC,et al.CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites[J].J Clin Pharmacol,2017,57(3):382-393.[4]Duconge J,Ramos AS,Claudio-Campos K,et al.A NovelAdmixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics[J].PLoS One,2016;11(1):e0145480.[5]Maekawa K,Adachi M,Matsuzawa Y,et al.Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9[J].Biochemistry,2017,56(41):5476-5480.[6]Dai DP,Li CB,Wang SH,et al.Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient[J].Pharmacogenomics,2015,16(13):1475-1486.[7]李志强,胡春燕.CYP2C9和VKORC1基因多态性对华法林抗凝治疗的影响[J].中国心血管病研究,2017(10):869-872.[8]De T,Park CS,Perera MA.Cardiovascular Pharmacogenomics: Does It Matter If You’re Black or White?[J].Annu Rev Pharmacol Toxicol,2019(59):577-603.[9]Dai DP,Xu RA,Hu LM,et al.CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database[J].Pharmacogenomics J,2014,14(1):85-92.[10]Shukla A,Jain A,Kahalekar V,et al.Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin[J].Hepatol Int,2019,13(2):214-221.[11]Jiang HH,Liu J,Wang YC,et al.The Impact of Gene Polymorphisms on Anticoagulation Control With Warfarin[J].Clin Appl ThrombHemost,2018,24(4):640-646.[12]Liu J,Jiang HH,Wu DK,et al.Effect of gene polymorphims on the warfarin treatment at initial stage[J].Pharmacogenomics J,2017,17(1):47-52.[13]Rad F,Hamidpour M,Dorgalaleh A,et al.The Effect of Demographic Factors and VKORC1 1639 G＞A Genotypes on Estimated Warfarin Maintenance Dose in Iranian Patients Under Warfarin Therapy[J].Indian J Hematol Blood Transfus,2019,35(1):167-171.[14]Dorji PW,Tshering G,Na-Bangchang K.CYP2C9,CYP2C19,CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review[J].J Clin Pharm Ther,2019,44(4):508-524.[15]Kocael A,Eronat AP,Tüzüner MB,et al.Interpretation of the effect of CYP2C9,VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey[J].Mol Biol Rep,2019,46(2):1825-1833.[16]Takeuchi M,Kobayashi T,Biss T,et al.CYP2C9,VKORC1,and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis[J].Pharmacogenomics J,2020,20(2):306-319.[17]Zhang J,Chen Z,Chen C.Impact of CYP2C9,VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis[J].Meta Gene,2016(9):197-209.[18]熊筱伟,刘红,韩璐璐,等.细胞色素P450酶4F2基因多态性对中国人服用华法林起始七天内剂量的影响[J].中国循环杂志,2014(11):910-912.[19]Li J,Yang W,Xie Z,et al.Impact of VKORC1,CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation[J].BMC Cardiovasc Disord,2018,18(1):96.[20]Yu WY,Sun X,Wadelius M,et al.Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta-Analysis[J].Cardiovasc Ther,2016,34(5):297-307.[21]Edin ML,Hamedani BG,Gruzdev A,et al.Epoxide hydrolase 1 (EPHX1) hydrolyzes epoxyeicosanoids and impairs cardiac recovery after ischemia[J].J Biol Chem,2018,293(9):3281-3292.[22]Chung JE,Lee KE,Chang BC,et al.Polymorphisms of vitamin K-related genes (EPHX1 and VKORC1L1) and stable warfarin doses[J].Gene,2018(641):68-73.[23]Lin X,Chen H,Ni L,et al.Effects of EPHX1 rs2260863 polymorphisms on warfarin maintenance dose in very elderly,frail Han-Chinese population[J].Pharmacogenomics,2020,21(12):863-870.[24]De Vilder EY,Debacker J,Vanakker OM.GGCX-Associated Phenotypes: An Overview in Search of Genotype-Phenotype Correlations[J].Int J Mol Sci,2017,18(2):240.[25]Jiang NX,Xu YH,Xia JW,et al.Impact of GGCX polymorphisms on warfarin dose requirements in atrial fibrillation patients[J].Turk J Med Sci,2017,47(4):1239-1246.[26]米力克扎提·吾甫尔,罗莉,木胡牙提?乌拉斯汉,等.新疆汉族房颤患者GGCX基因rs11676382多态性及其与华法林稳定剂量相关性研究[J].医学分子生物学杂志,2015(4):202-206.[27]李文慧,许冰莹,邓建强,等.云南汉族人群GGCX(rs699664)基因多态性与华法林抗凝治疗剂量的相关性研究[J].现代诊断与治疗,2014(14):3121-3123.[28]Yu Z,Seya K,Chiyoya M,et al.Warfarin calcifies human aortic valve interstitial cells at high-phosphate conditions via pregnane X receptor[J].J Bone Miner Metab,2019,37(6):944-956.[29]Zhou L,Chen L,Wang Y,et al.Impact of NR1I2,adenosine triphosphate-binding cassette transporters genetic polymorphisms on the pharmacokinetics of ginsenoside compound K in healthy Chinese volunteers[J].J Ginseng Res,2019,43(3):460-474.[30]Moon JY,Chang BC,Lee KE,et al.Effects of Pregnane X Receptor Genetic Polymorphisms on Stable Warfarin Doses[J].J Cardiovasc Pharmacol Ther,2015,20(6):532-538.[31]Zeng WT,Xu Q,Li CH,et al.Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese[J].Eur J Clin Pharmacol,2016,72(11):1327-1334.[32]胡蓉,许哲,赵立子,等.POR基因多态性与华法林维持剂量关系的研究[J].中国药理学通报,2014,30(5):706-710.[33]Baranova EV,Verhoef TI,Ragia G,et al.Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes[J].J ThrombHaemost,2017,15(3):465-472.[34]International Warfarin Pharmacogenetics Consortium,Klein TE,Altman RB,et al.Estimation of the warfarin dose with clinical and pharmacogenetic data[J].N Engl J Med,2009,360(8):753-764.

相似文献/References:

[1]王新宇,刘光宇.华法林过量致自发性小肠壁内血肿的MSCT表现[J].医学信息,2018,31(21):161.[doi:10.3969/j.issn.1006-1959.2018.21.047]
　WANG Xinyu,LIU Guangyu.Spontaneous Intramural Hematoma of Small Bowel Secondary to Excessive Warfarin Therapy: MSCT Manifestations and Its Clinical Value[J].Medical Information,2018,31(20):161.[doi:10.3969/j.issn.1006-1959.2018.21.047]
[2]周 笳,董丽霞.阿替普酶联合华法林治疗慢阻肺合并肺栓塞的有效性分析[J].医学信息,2019,32(05):146.[doi:10.3969/j.issn.1006-1959.2019.05.046]
　ZHOU Jia,DONG Li-xia.Efficacy Analysis of Alteplase Combined with Warfarin in the Treatment of Chronic Obstructive Pulmonary Disease with Pulmonary Embolism[J].Medical Information,2019,32(20):146.[doi:10.3969/j.issn.1006-1959.2019.05.046]
[3]邹 璐,姚黎清.心血管药物基因多态性与脑卒中相关性研究进展[J].医学信息,2022,35(07):15.[doi:10.3969/j.issn.1006-1959.2022.07.004]
　ZOU Lu,YAO Li-qing.Research Progress on the Correlation Between Cardiovascular Drug Gene Polymorphism and Stroke[J].Medical Information,2022,35(20):15.[doi:10.3969/j.issn.1006-1959.2022.07.004]
[4]王东旭.华法林抗凝治疗与CYP2C9基因多态性的研究[J].医学信息,2023,36(02):176.[doi:10.3969/j.issn.1006-1959.2023.02.039]
　WANG Dong-xu.Research in Warfarin Anticoagulant Treatment and Genetic Polymorphisms of CYP2C9[J].Medical Information,2023,36(20):176.[doi:10.3969/j.issn.1006-1959.2023.02.039]

更新日期/Last Update: 1900-01-01